Phaseline

Companies › Tavotek Biotherapeutics

Tavotek Biotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology, Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TAVO101–Phase 2Atopic Dermatitis–
TAVO412–Phase 1Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06176040TAVO101Phase 2Atopic DermatitisImmunologyMar 2025
NCT06761651TAVO412Phase 1CancerOncologyJan 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Xizang Haisco Pharmaceutical Telios Pharma Molecure Antengene Biologics Ganzhou Hemay Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.